大学化学 >> 2024, Vol. 39 >> Issue (12): 202-207.doi: 10.12461/PKU.DXHX202403099

所属专题： 高分子与生命健康

知识介绍 上一篇    下一篇

单抗药物：生物医药领域的突破与希望

张雨欣1, 黄浩铖1, 张文卓1, 周禄顺1, 林亚维1, 何振宇2   

  1. 1 武汉理工大学化学化工与生命科学学院, 武汉 430070;
    2 武汉市疾病预防控制中心, 武汉 430060
  • 收稿日期:2024-03-27 录用日期:2024-07-04 发布日期:2024-12-17
  • 通讯作者: 林亚维, 何振宇 E-mail:linyawei2012@whut.edu.cn;hosan9174@163.com
  • 基金资助:
    湖北省卫健委预防专项重大项目(WJ2019H303);武汉预防医学科研专项(WY19M01)

Monoclonal Antibody Drugs: Breakthroughs and Hope in the Field of Biomedical Sciences

Yuxin Zhang1, Haocheng Huang1, Wenzhuo Zhang1, Lushun Zhou1, Yawei Lin1, Zhenyu He2   

  1. 1 School of Chemistry, Chemical Engineering & Life Sciences, Wuhan University of Technology, Wuhan 430070, China;
    2 Wuhan Center for Disease & Prevention, Wuhan 430060, China
  • Received:2024-03-27 Accepted:2024-07-04 Published:2024-12-17
  • Contact: Yawei Lin, Zhenyu He E-mail:linyawei2012@whut.edu.cn;hosan9174@163.com

PDF

267

赞

摘要： 相较传统药物而言，单抗药物以其出色的特异性脱颖而出。它不仅能够特异性地识别并结合目标抗原，精准地定位到病变部位，还能针对特定的疾病过程进行干预，减少药物对其他部位的损伤，降低其副作用。单抗药物在疾病预防和治疗中扮演着重要角色，其结构功能独特，制备流程严谨，安全性得到广泛认可。本文介绍了单抗药物的结构功能以及制备流程等内容，并着重论述了单抗药物在治疗肿瘤疾病、自身免疫疾病和感染性疾病方面的贡献。

关键词: 单克隆抗体, 单抗药物的制备, 单抗药物的质量控制

Abstract: Compared to traditional drugs, monoclonal antibody (mAb) drugs distinguish themselves through their excellent specificity. They are capable of precisely recognizing and binding to target antigens, accurately localizing to diseased sites, and intervening in specific disease processes, thereby minimizing damage to other parts of the body and reducing side effects. MAb drugs play an important role in disease prevention and treatment, characterized by their unique structural functions, stringent preparation processes, and widely acknowledged safety. This article introduces the structure and functions of mAb drugs, along with their preparation processes, and emphasizes their significant contributions to the treatment of tumor, autoimmune diseases, and infectious diseases.

Key words: Monoclonal antibody, Preparation of monoclonal antibody drugs, Quality control of monoclonal antibody drugs